Evidence map›Paper›PMID 39932596›Full record

ReviewRheumatology international2025

Thyroid disease as a comorbidity in inflammatory rheumatic diseases.

Yuliya Fedorchenko, Marlen Yessirkepov, Bohdana Doskaliuk, Liubomyr Zaiats, Khaiyom Mahmudov

Abstract readReview
PubMed Publisher
In one paragraph

Review in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuliya FedorchenkoDepartment of Pathophysiology, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine. juliakozubash@gmail.com.ORCID 0000-0002-5042-1191
Marlen YessirkepovDepartment of Biology and Biochemistry, South Kazakhstan Medical Academy, Shymkent, Kazakhstan.ORCID 0000-0003-2511-6918
Bohdana DoskaliukDepartment of Pathophysiology, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine.ORCID 0000-0003-1650-8928
Liubomyr ZaiatsDepartment of Pathophysiology, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine.ORCID 0000-0003-3265-1273
Khaiyom MahmudovDepartment of Propaedeutics of Internal Diseases, Avicenna Tajik State Medical University, Dushanbe, Tajikistan.ORCID 0000-0002-3583-9442

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid disease is a common comorbidity in inflammatory rheumatic diseases (IRDs). It complicates disease management and treatment of IRDs. The interplay between thyroid disfunction and IRDs is confounded by shared autoimmune mechanisms and systemic inflammation. Available evidence suggests that rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and systemic sclerosis (SSc) are associated with an elevated risk of hypothyroidism, hyperthyroidism, and autoimmune thyroid disease (AITD). This review explores mechanisms of thyroid disease in IRDs, overviews implications for disease management, and highlights approaches to optimal patient outcomes. Recent studies point to the need for routine thyroid screening in high-risk IRD populations and justify therapies with anti-TNF-α and anti-IL-17 agents, targeting both thyroid disease and IRDs. This integrated management strategy is crucial for optimizing therapeutic approaches in overlapping autoimmune conditions.

Indexed as

Rheumatic DiseasesThyroid DiseasesComorbidityHumansAutoimmune thyroid diseaseRheumatic diseasesRheumatoid arthritisSystemic lupus erythematosusThyroid hormone

Identifiers

PMID39932596

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.